Publications
- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma +12022 | Faculty of Medicine in Hradec Králové
- Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Adjuvant therapy of malignant melanoma: general and practical experience2021 | Faculty of Medicine in Hradec Králové
- How to manage side effects of immunotherapy How to manage side effects of immunotherapy2020 | Faculty of Medicine in Hradec Králové
- Real-accesible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic2020 | Faculty of Medicine in Hradec Králové
- Hepatic Injury Induced by a Single Dose of Nivolumab - a Case Report and Literature Review2019 | Faculty of Medicine in Hradec Králové
- Complete remission of metastatic malignant melanoma treated with nivolumab, complicated with pulmonary toxicity2018 | Faculty of Medicine in Hradec Králové
- Nivolumab induced encephalopathy in a man with metastatic renal celll cancer: a case report2018 | Faculty of Medicine in Hradec Králové
- Pembrolizumab in pretreated patient2018 | Faculty of Medicine in Hradec Králové
Loading network view...